Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma

Primary Angle Closure Glaucoma Clinical Trial

Official title: Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma

Status Completed

Clinical Trial Summary

This study is a prospective evaluation of the Hydrus Microstent for the treatment of Primary Angle Closure (PAC) and Primary Angle Closure Glaucoma (PACG) with adjunctive cataract. A total of 20 subjects will be successfully treated with one Hydrus device after completion of cataract extraction with phacoemulsification followed by IOL replacement (HMS cohort), and 10 eyes will be treated with phacoemulsification cataract extraction and IOL replacement only (PCS group). Since cataract surgery is standard of care for this condition, eligible fellow eyes from the HMS cohort may be enrolled into the PCS group. To avoid selection bias in this non-randomized study, the first 20 consecutive qualifying subjects will be treated with Hydrus and the next 10 consecutive qualifying eyes will be treated with cataract surgery only.

Clinical Trial Description

The objective of this study is to assess the effectiveness of the Hydrus Microstent for lowering intraocular pressure in patients with PAC or PACG. The addition of the Hydrus is expected to lower IOP and medication dependency, and thus reduce the risk of progression of glaucoma. The PCS group will provide a control group to assess the magnitude of the Hydrus treatment effect on IOP, medications, and safety. Upon successfully meeting the study inclusion/exclusion criteria at both the screening and baseline visits, the subject will be scheduled for surgery. Follow up will be continued for 1 year post surgery, and will include assessments of the subject's IOP, ocular health, and visual acuity status. Visits will be conducted at 1, 7, 30, 90, 180, and 365 days. A 20% drop in IOP in response to therapy is considered clinically meaningful. The study treatment will be considered successful if a patient can obtain this response in IOP using the same or a fewer number of medications as pre-operative baseline. ;

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Angle-Closure
• Primary Angle Closure
• Primary Angle Closure Glaucoma

• NCT number: NCT04622605
• Study type: Interventional
• Source: Asian Eye Institute
• Status: Completed
• Phase: N/A
• Start date: June 13, 2017
• Completion date: December 23, 2021